HUP0104390A2 - Alfa-2B vagy alfa-2B/2C adrenerg receptorokra nézve szelektív agonista aktivitással rendelkező imidazolszármazékok és alkalmazásuk - Google Patents
Alfa-2B vagy alfa-2B/2C adrenerg receptorokra nézve szelektív agonista aktivitással rendelkező imidazolszármazékok és alkalmazásukInfo
- Publication number
- HUP0104390A2 HUP0104390A2 HU0104390A HUP0104390A HUP0104390A2 HU P0104390 A2 HUP0104390 A2 HU P0104390A2 HU 0104390 A HU0104390 A HU 0104390A HU P0104390 A HUP0104390 A HU P0104390A HU P0104390 A2 HUP0104390 A2 HU P0104390A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alpha
- formula
- atom
- alkyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 title 1
- 102000017910 Adrenergic receptor Human genes 0.000 title 1
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 abstract 3
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 208000001780 epistaxis Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A tal lm ny (I) ltal nos képletű vegyületekre vonatkozik. A képletben- adott esetben jelenlevő kettősk"tést képvisel, R jelentésehidrogénatom vagy alkilcsoport, X jelentése kénatom vagy C(H)R1 ltalnos képletű csoport, ahol R1 jelentése hidrogénatom vagy alkilcsoport,Y jelentése oxigén-, nitrogén- vagy kénatom, (CR12)y ltal nos képletűcsoport, ahol y értéke 1-3, -CH=CH- vagy -Y1CH2- ltal nos képletűcsoport, ahol Y1 jelentése oxigén-, nitrogén- vagy kénatom, x értéke 1vagy 2, bizonyos megk"tésekkel R2 jelentése hidrogén- vagyhalogénatom, hidroxil-, alkil-, alkoxi-, alkenil-, acil-,alkinilcsoport vagy amennyiben egy telített szénatomhoz kapcsolódik,akkor oxocsoport, R3 és R4 jelentése hidrogén- vagy halogénatom,alkil-, alkenil-, acil-, alkinilcsoport, adott esetben helyettesítettarilcsoport, heteroarilcsoport, vagy pedig együttesen[C(R2)x]z-; -Y1[C(R2)x]z'-; -Y1[C(R2)x]yY1-; -[C(R2)x]-Y1[C(R2)x]-; -[C(R2)x]-Y1-[C(R2)x]-vagy -Y1-[C(R2)x]-Y1-[C(R2)x]- ltal nos képletű csoportotképviselnek, tov bb az említett kétértékű csoportok b rmelyik végekapcsolódhat R3 vagy R4 szubsztituens b rmelyikéhez, és így egykondenz lt gyűrűrendszert alkothat. A vegyületek szelektív agonistaaktivit ssal rendelkeznek "nmag ban az alfa-2B adrenerg receptoraltípusokra, vagy pedig az alfa-2B és alfa-2C adrenerg receptoraltípusokra nézve, így olyan gyógyszerkészítmények hatóanyagakéntalkalmazhatók, amelyek glaukoma, szemen belüli nyom s cs"kkentése,krónikus f jdalom, hasmenés és orrvérzés, tov bb izomg"rcs"k, megvonsi tünetek, f jdalmak, neuro- degeneratív betegségek, félelmet,depressziót, magas vérnyom s, vértolul sos szívelégtelenség ésszíviszkémia kezelésére és megelőzésére alkalmazhatók, anélkül, hogyszedatív vagy kardiovaszkul ris mellékhat sokat okozn nak. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32975299A | 1999-06-10 | 1999-06-10 | |
| PCT/US2000/015795 WO2001000586A1 (en) | 1999-06-10 | 2000-06-08 | Compounds as selective agonists at alpha 2b or 2b/2c adrenergic receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0104390A2 true HUP0104390A2 (hu) | 2002-04-29 |
| HUP0104390A3 HUP0104390A3 (en) | 2002-05-28 |
Family
ID=23286854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0104390A HUP0104390A3 (en) | 1999-06-10 | 2000-06-08 | Imidazole derivatives as selective agonists at alpha 2b or 2b/2c adrenergic receptors |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1104407B1 (hu) |
| AT (1) | ATE283843T1 (hu) |
| AU (1) | AU773668B2 (hu) |
| CZ (1) | CZ2001864A3 (hu) |
| DE (1) | DE60016359T2 (hu) |
| ES (1) | ES2228544T3 (hu) |
| HK (1) | HK1035724A1 (hu) |
| HU (1) | HUP0104390A3 (hu) |
| RU (1) | RU2232154C2 (hu) |
| TW (1) | TWI283669B (hu) |
| WO (1) | WO2001000586A1 (hu) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| AU2002254265B2 (en) * | 1997-12-04 | 2008-05-15 | Allergan, Inc. | Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors |
| US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| US6534542B2 (en) | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| WO2005039567A1 (en) * | 2003-10-08 | 2005-05-06 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| BRPI0510212A (pt) * | 2004-05-07 | 2007-10-16 | Memory Pharm Corp | 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos |
| EP1797043A1 (en) | 2004-09-24 | 2007-06-20 | Allergan, Inc. | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
| NZ553290A (en) * | 2004-09-24 | 2010-11-26 | Allergan Inc | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| JP2008514603A (ja) | 2004-09-24 | 2008-05-08 | アラーガン、インコーポレイテッド | α２アドレナリン作動剤としての４−（ヘテロアリール−メチルおよび置換ヘテロアリール−メチル）−イミダゾール−２−チオン |
| KR101202066B1 (ko) | 2004-09-28 | 2012-11-15 | 알러간, 인코포레이티드 | 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법 |
| US7390829B2 (en) | 2005-06-29 | 2008-06-24 | Allergan, Inc. | Alpha-2 adrenergic agonists |
| KR20080039982A (ko) * | 2005-08-25 | 2008-05-07 | 쉐링 코포레이션 | 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체 |
| PE20070519A1 (es) | 2005-08-25 | 2007-07-13 | Schering Corp | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| US7592362B2 (en) | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
| US7323477B2 (en) | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
| CA2669112A1 (en) | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
| US7868020B2 (en) | 2007-01-12 | 2011-01-11 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
| US8119807B2 (en) | 2007-01-12 | 2012-02-21 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
| US8013169B2 (en) | 2007-01-12 | 2011-09-06 | Allergan, Inc | Naphthylmethylimidizoles as therapeutic agents |
| MX2009008776A (es) | 2007-02-13 | 2009-08-25 | Schering Corp | Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
| WO2008100459A1 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| WO2008100456A2 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| EP2155715B1 (en) * | 2007-05-14 | 2013-03-13 | Allergan, Inc. | ((phenyl)imidazolyl)methylheteroaryl compounds |
| JP5433576B2 (ja) * | 2007-08-15 | 2014-03-05 | アラーガン インコーポレイテッド | アドレナリン作動化合物 |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| DK2250153T3 (da) * | 2008-01-18 | 2013-09-16 | Allergan Inc | Substituerede aryl-(imidazol)-methyl)-phenylforbindelser som subtype-selektive modulatorer af alpha 2b og/eller alpha 2 c-adrenerge receptorer |
| EP2257546B1 (en) | 2008-02-21 | 2012-08-15 | Merck Sharp & Dohme Corp. | Functionally selective alpha2c adrenoreceptor agonists |
| WO2010042473A1 (en) | 2008-10-07 | 2010-04-15 | Schering Corporation | Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators |
| US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| MX2020004666A (es) | 2017-11-17 | 2022-01-26 | Cellix Bio Private Ltd | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| JPH01242571A (ja) * | 1988-03-22 | 1989-09-27 | Mitsui Petrochem Ind Ltd | イミダゾール誘導体の製造方法 |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US5750720A (en) * | 1996-03-28 | 1998-05-12 | Ortho Pharmaceutical Corporation | 4- (thien-3-yl)methyl!-imidazole analgesics |
| US5621113A (en) * | 1996-03-28 | 1997-04-15 | Ortho Pharmaceutical Corporation | 4-[(thien-2-yl)methyl]-imidazole analgesics |
| KR20000069426A (ko) * | 1997-10-02 | 2000-11-25 | 이시가와 데쯔로 | 신규의 디히드로나프탈렌 화합물 및 그 제조방법 |
| EP1413576A3 (en) * | 1997-12-04 | 2004-09-01 | Allergan, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
-
2000
- 2000-06-07 TW TW089111068A patent/TWI283669B/zh not_active IP Right Cessation
- 2000-06-08 AT AT00939699T patent/ATE283843T1/de not_active IP Right Cessation
- 2000-06-08 HU HU0104390A patent/HUP0104390A3/hu unknown
- 2000-06-08 WO PCT/US2000/015795 patent/WO2001000586A1/en active IP Right Grant
- 2000-06-08 ES ES00939699T patent/ES2228544T3/es not_active Expired - Lifetime
- 2000-06-08 CZ CZ2001864A patent/CZ2001864A3/cs unknown
- 2000-06-08 EP EP00939699A patent/EP1104407B1/en not_active Expired - Lifetime
- 2000-06-08 AU AU54749/00A patent/AU773668B2/en not_active Ceased
- 2000-06-08 DE DE60016359T patent/DE60016359T2/de not_active Expired - Lifetime
- 2000-06-08 RU RU2001107028/04A patent/RU2232154C2/ru not_active IP Right Cessation
-
2001
- 2001-09-07 HK HK01106343A patent/HK1035724A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1035724A1 (en) | 2001-12-07 |
| HUP0104390A3 (en) | 2002-05-28 |
| AU5474900A (en) | 2001-01-31 |
| ES2228544T3 (es) | 2005-04-16 |
| EP1104407B1 (en) | 2004-12-01 |
| ATE283843T1 (de) | 2004-12-15 |
| RU2232154C2 (ru) | 2004-07-10 |
| EP1104407A1 (en) | 2001-06-06 |
| CZ2001864A3 (cs) | 2001-09-12 |
| TWI283669B (en) | 2007-07-11 |
| DE60016359T2 (de) | 2005-12-01 |
| WO2001000586A1 (en) | 2001-01-04 |
| DE60016359D1 (de) | 2005-01-05 |
| AU773668B2 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0104390A2 (hu) | Alfa-2B vagy alfa-2B/2C adrenerg receptorokra nézve szelektív agonista aktivitással rendelkező imidazolszármazékok és alkalmazásuk | |
| EP1027363B1 (en) | Adenosine a1-receptor agonists | |
| GEP20032958B (en) | Adenosine Derivatives | |
| WO2002022805A3 (en) | Modulation of il-2- and il-15-mediated t cell responses | |
| KR960704884A (ko) | 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents) | |
| MA26861A1 (fr) | Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires | |
| HUP0203965A2 (en) | Indazole compounds and pharmaceutical compositions containing them | |
| KR890001537A (ko) | 5ht-3 길항제의 용도 | |
| HUP0203841A2 (en) | 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them | |
| HUP0203870A2 (hu) | Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény | |
| DK0760811T3 (da) | Imidazolderivater som histaminreceptor H3-modulatorer | |
| DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
| UA66945C2 (uk) | ПОХІДНІ ПУРИНУ З ВЛАСТИВОСТЯМИ АГОНІСТА ЛЮДСЬКОГО А2<sub>А</sub> РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ | |
| HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| MA27443A1 (fr) | Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| ATE298562T1 (de) | Hydrogelpartikel formulierungen | |
| BR9813976A (pt) | Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto. | |
| PT975602E (pt) | Derivados de imidazole e de imidazolina e suas utilizacoes | |
| TR200003383T2 (tr) | HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler. | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| KR880012227A (ko) | 도파민 수용체 길항제의 신규사용법 | |
| HUP0100558A2 (hu) | S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben | |
| BRPI0417161A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| DK1303278T3 (da) | Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme | |
| SE9904421D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |